These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 28029415)

  • 21. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
    Wranik WD; Gambold L; Peacock S
    Health Policy; 2021 Mar; 125(3):307-319. PubMed ID: 33388158
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of health technology assessment in the process of implementation of the EU Transparency Directive: relevant experience from Central Eastern European countries.
    Kolasa K; Kalo Z; Zah V; Dolezal T
    Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):283-7. PubMed ID: 22812552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attitudes toward supplementary criteria in the reimbursement process in Poland.
    Kolasa K; Annemans L; Lees M
    Int J Technol Assess Health Care; 2013 Oct; 29(4):443-9. PubMed ID: 24290338
    [No Abstract]   [Full Text] [Related]  

  • 24. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
    Allen N; Walker SR; Liberti L; Salek S
    Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What Influences Recommendations Issued by the Agency for Health Technology Assessment in Poland? A Glimpse Into Decision Makers' Preferences.
    Niewada M; Polkowska M; Jakubczyk M; Golicki D
    Value Health Reg Issues; 2013; 2(2):267-272. PubMed ID: 29702876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug Policy in Estonia.
    Mägi K; Lepaste M; Szkultecka-Dębek M
    Value Health Reg Issues; 2018 Sep; 16():1-4. PubMed ID: 29529444
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges to decision-making processes in the national HTA agency in Brazil: operational procedures, evidence use and recommendations.
    Yuba TY; Novaes HMD; de Soárez PC
    Health Res Policy Syst; 2018 May; 16(1):40. PubMed ID: 29751764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH common drug review.
    Janoudi G; Amegatse W; McIntosh B; Sehgal C; Richter T
    Orphanet J Rare Dis; 2016 Dec; 11(1):164. PubMed ID: 27908281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.
    Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
    Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.
    Malinowski KP; Kawalec P; Trabka W; Sowada C; Pilc A
    Front Pharmacol; 2018; 9():1263. PubMed ID: 30483124
    [No Abstract]   [Full Text] [Related]  

  • 31. Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines.
    Lach K; Dziwisz M; Rémuzat C; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1355202. PubMed ID: 28804603
    [No Abstract]   [Full Text] [Related]  

  • 32. The politics of health technology assessment in Poland.
    Ozieranski P; McKee M; King L
    Health Policy; 2012 Dec; 108(2-3):178-93. PubMed ID: 23127957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.
    Linley WG; Hughes DA
    Pharmacoeconomics; 2012 Sep; 30(9):779-94. PubMed ID: 22676385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pitfalls in reimbursement decisions for oncology drugs in South Korea: need for addressing the ethical dimensions in technology assessment.
    Cho E; Park EC; Kang MS
    Asian Pac J Cancer Prev; 2013; 14(6):3785-92. PubMed ID: 23886183
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reimbursement decision-making system in Poland systematically compared to other countries.
    Mela A; Rdzanek E; Jaroszyński J; Furtak-Niczyporuk M; Jabłoński M; Niewada M
    Front Pharmacol; 2023; 14():1153680. PubMed ID: 37900165
    [No Abstract]   [Full Text] [Related]  

  • 38. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Better defining target populations for drugs with a view to reimbursement.
    Massol J; Boissel JP
    Therapie; 2014; 69(3):235-7. PubMed ID: 24927505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similarities and differences between five European drug reimbursement systems.
    Franken M; le Polain M; Cleemput I; Koopmanschap M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):349-57. PubMed ID: 22989410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.